The Iron-Fueled Heart: Ferroptosis Emerges as a Key Driver of Cardiac Decline
A comprehensive review in Cardiovascular Research synthesizes the growing evidence implicating ferroptosis—a form of iron-dependent, lipid peroxidation-driven cell death—in the progression of heart failure. The analysis highlights that this process is prevalent across diverse heart failure models, from ischemic and pressure-overloaded hearts to those affected by metabolic disorders like diabetes and obesity. The proposed “ferroptosis nexus” describes a vicious cycle where iron overload, antioxidant system collapse, and mitochondrial dysfunction converge to damage heart muscle cells, leading to impaired contractility and adverse remodeling. Notably, several established heart failure therapies, including SGLT2 inhibitors and sacubitril/valsartan, appear to exert part of their benefit by mitigating this specific cell death pathway, offering a unifying mechanistic hypothesis for their clinical efficacy.
Why it might matter to you: For a gastroenterologist, the detailed exploration of systemic metabolic and inflammatory pathways in heart failure provides a crucial parallel for understanding similar processes in chronic liver diseases like NAFLD/NASH and cirrhosis. The concept of a self-reinforcing “nexus” of cell death mirrors the pathogenic loops seen in hepatocyte injury and fibrogenesis. This research underscores the importance of looking beyond the gastrointestinal tract, as cardiometabolic complications are a leading cause of mortality in patients with advanced liver disease, and shared mechanisms like ferroptosis could reveal novel therapeutic targets relevant to hepatology.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
